Published in FASEB J on January 22, 2003
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 3.80
Viral tricks to grid-lock the type I interferon system. Curr Opin Microbiol (2010) 2.17
Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. PLoS Pathog (2008) 1.94
Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol (2006) 1.87
Generation of infectious hepatitis C virus in immortalized human hepatocytes. J Virol (2006) 1.86
Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem (2010) 1.76
Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev (2007) 1.65
Mouse hepatitis coronavirus A59 nucleocapsid protein is a type I interferon antagonist. J Virol (2006) 1.53
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int (2010) 1.48
Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology (2006) 1.47
Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J Interferon Cytokine Res (2009) 1.42
Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B. Clinics (Sao Paulo) (2013) 1.40
An overview of HCV molecular biology, replication and immune responses. Virol J (2011) 1.37
Induction of suppressor of cytokine signaling-3 by herpes simplex virus type 1 contributes to inhibition of the interferon signaling pathway. J Virol (2004) 1.36
Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling. PLoS One (2010) 1.29
Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model. J Immunol (2008) 1.27
Oncogenic potential of hepatitis C virus proteins. Viruses (2010) 1.22
Viral RNA silencing suppressors (RSS): novel strategy of viruses to ablate the host RNA interference (RNAi) defense system. Virus Res (2010) 1.17
HCV causes chronic endoplasmic reticulum stress leading to adaptation and interference with the unfolded protein response. PLoS One (2011) 1.13
Hepatitis C virus infection impairs IRF-7 translocation and Alpha interferon synthesis in immortalized human hepatocytes. J Virol (2010) 1.11
Differential regulation of SOCS-1 signalling in B and T lymphocytes by hepatitis C virus core protein. Immunology (2008) 1.10
Gene expression and hepatitis C virus infection. Gut (2008) 1.08
Mechanisms of HCV survival in the host. Nat Rev Gastroenterol Hepatol (2009) 1.07
Innate immune responses in hepatitis C virus infection. Semin Immunopathol (2012) 1.06
dsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection. Viruses (2012) 1.05
Mycobacterium avium subsp. paratuberculosis inhibits gamma interferon-induced signaling in bovine monocytes: insights into the cellular mechanisms of Johne's disease. Infect Immun (2012) 1.05
Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells. Liver Int (2008) 1.05
SOCS1, a Negative Regulator of Cytokine Signals and TLR Responses, in Human Liver Diseases. Gastroenterol Res Pract (2010) 1.04
Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol (2008) 1.02
Viral exploitation of host SOCS protein functions. J Virol (2010) 1.01
Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. J Virol (2011) 1.01
Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner. J Virol (2010) 0.99
Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J Hepatol (2009) 0.98
Retracted SOCS1 and SOCS3 are targeted by hepatitis C virus core/gC1qR ligation to inhibit T-cell function. J Virol (2005) 0.94
Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. Cell Mol Immunol (2014) 0.94
Hepatitis C virus and ethanol alter antigen presentation in liver cells. World J Gastroenterol (2009) 0.94
Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy. J Virol (2011) 0.92
Elucidating novel hepatitis C virus-host interactions using combined mass spectrometry and functional genomics approaches. Mol Cell Proteomics (2013) 0.92
Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol (2008) 0.92
Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway. J Virol (2011) 0.90
Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes. J Virol (2006) 0.90
Non-encapsidation activities of the capsid proteins of positive-strand RNA viruses. Virology (2013) 0.89
Interaction of hepatitis C virus with the type I interferon system. World J Gastroenterol (2007) 0.88
Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype. J Virol (2013) 0.88
Hepatitis C virus attenuates interferon-induced major histocompatibility complex class I expression and decreases CD8+ T cell effector functions. Gastroenterology (2014) 0.86
Interferon alpha regulates MAPK and STAT1 pathways in human hepatoma cells. Virol J (2011) 0.86
Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients. J Hepatol (2010) 0.82
Epstein-Barr virus interferes with the amplification of IFNalpha secretion by activating suppressor of cytokine signaling 3 in primary human monocytes. PLoS One (2010) 0.81
Helicobacter pylori VacA suppresses Lactobacillus acidophilus-induced interferon beta signaling in macrophages via alterations in the endocytic pathway. MBio (2013) 0.81
Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies. World J Hepatol (2012) 0.81
HCV innate immune responses. Viruses (2009) 0.80
Mechanisms underlying the inhibition of interferon signaling by viruses. Virulence (2014) 0.80
Innate immunity and hepatitis C virus infection: a microarray's view. Infect Agent Cancer (2012) 0.80
The role of HCV proteins on treatment outcomes. Virol J (2015) 0.78
Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response. PLoS One (2015) 0.78
Host restriction factors for hepatitis C virus. World J Gastroenterol (2016) 0.78
Specific targeting of hepatitis C virus core protein by an intracellular single-chain antibody of human origin. Hepatology (2008) 0.78
Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. World J Hepatol (2015) 0.78
Correlation between the suppressor of cytokine signaling-1 and 3 and hepatitis B virus: possible roles in the resistance to interferon treatment. Virol J (2014) 0.78
Japanese encephalitis virus upregulates the expression of SOCS3 in mouse brain and Raw264.7 Cells. Viruses (2014) 0.78
Regulation of host innate immunity by hepatitis C virus: crosstalk between hepatocyte and NK/DC. Rev Infect (2010) 0.77
Function of the Herpes Simplex Virus 1 Small Capsid Protein VP26 Is Regulated by Phosphorylation at a Specific Site. J Virol (2015) 0.77
Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am (2015) 0.77
The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients. Hepat Mon (2016) 0.77
Hepatitis C, innate immunity and alcohol: friends or foes? Biomolecules (2015) 0.77
Human Interferon Regulatory Factor 2 Gene Expression is Induced in Chronic Hepatitis C Virus Infection-A Possible Mode of Viral Persistence. J Clin Exp Hepatol (2012) 0.77
Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies. World J Exp Med (2012) 0.76
The impact of host factors on management of hepatitis C virus. Hepat Mon (2012) 0.76
Comparative study of synonymous codon usage variations between the nucleocapsid and spike genes of coronavirus, and C-type lectin domain genes of human and mouse. Exp Mol Med (2009) 0.76
Impact of host and virus genome variability on HCV replication and response to interferon. Curr Opin Virol (2013) 0.76
SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B. Oncotarget (2017) 0.75
Combination antiretroviral therapy (cART) restores HIV-1 infection-mediated impairment of JAK-STAT signaling pathway. Oncotarget (2017) 0.75
Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists. Vaccines (Basel) (2016) 0.75
Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Sci Rep (2016) 0.75
Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy. Int J Mol Sci (2015) 0.75
Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy. Virol J (2015) 0.75
Influence of host resistance on viral adaptation: hepatitis C virus as a case study. Infect Drug Resist (2015) 0.75
Progress in the development of vaccines for hepatitis C virus infection. World J Gastroenterol (2015) 0.75
Long Non-coding RNAs in Hepatitis C Virus-Infected Cells. Front Microbiol (2017) 0.75
Hepatitis C virus induces a pre-diabetic state by directly impairing hepatic glucose metabolism in mice. J Biol Chem (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J (2003) 10.77
Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med (2007) 5.47
Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology (2008) 4.53
Congenital glutamine deficiency with glutamine synthetase mutations. N Engl J Med (2005) 3.24
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology (2004) 3.19
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med (2011) 2.72
CD133+ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun (2006) 2.54
Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol (2011) 2.51
Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. J Virol (2007) 2.44
Caspase 3 activation is essential for efficient influenza virus propagation. EMBO J (2003) 2.38
Rickettsia felis infection acquired in Europe and documented by polymerase chain reaction. Emerg Infect Dis (2002) 2.26
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19
Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology (2002) 2.16
Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med (2007) 2.14
The influenza A virus NS1 protein inhibits activation of Jun N-terminal kinase and AP-1 transcription factors. J Virol (2002) 2.14
iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science (2012) 2.14
An obligatory requirement for the heterotrimeric G protein Gi3 in the antiautophagic action of insulin in the liver. Proc Natl Acad Sci U S A (2007) 2.10
Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci U S A (2011) 1.98
Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. PLoS Pathog (2008) 1.94
Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence. Cell Microbiol (2006) 1.94
Integrated metabolic spatial-temporal model for the prediction of ammonia detoxification during liver damage and regeneration. Hepatology (2014) 1.93
Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol (2003) 1.92
The proapoptotic influenza A virus protein PB1-F2 regulates viral polymerase activity by interaction with the PB1 protein. Cell Microbiol (2008) 1.90
Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun (2008) 1.83
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology (2005) 1.79
Hepatic stellate cells contribute to progenitor cells and liver regeneration. J Clin Invest (2014) 1.77
Amino acids in nectar enhance butterfly fecundity: a long-awaited link. Am Nat (2005) 1.76
The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells. PLoS Pathog (2010) 1.73
Hepatic acute phase proteins--regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. Eur J Cell Biol (2011) 1.71
MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood (2004) 1.71
The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology (2007) 1.69
Early clinical experiences with the new influenza A (H1N1/09). Dtsch Arztebl Int (2009) 1.65
Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology (2010) 1.65
Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol (2004) 1.64
The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology (2009) 1.62
Lipopolysaccharide-induced tyrosine nitration and inactivation of hepatic glutamine synthetase in the rat. Hepatology (2005) 1.62
NF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation. J Biol Chem (2004) 1.59
Ultrasound in tropical and parasitic diseases. Lancet (2003) 1.59
Transcriptional profiling of IKK2/NF-kappa B- and p38 MAP kinase-dependent gene expression in TNF-alpha-stimulated primary human endothelial cells. Blood (2004) 1.56
Intrahepatic synthesis of tumor necrosis factor-alpha related to cardiac surgery is inhibited by interleukin-10 via the Janus kinase (Jak)/signal transducers and activator of transcription (STAT) pathway. Crit Care Med (2003) 1.56
Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. J Hepatol (2004) 1.55
Benzodiazepine-induced protein tyrosine nitration in rat astrocytes. Hepatology (2003) 1.53
Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr (2006) 1.53
Involvement of NADPH oxidase isoforms and Src family kinases in CD95-dependent hepatocyte apoptosis. J Biol Chem (2005) 1.53
Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells (2005) 1.53
A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway. Cell Microbiol (2009) 1.50
α5 β1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes. Hepatology (2012) 1.50
Viral targeting of the interferon-{beta}-inducing Traf family member-associated NF-{kappa}B activator (TANK)-binding kinase-1. Proc Natl Acad Sci U S A (2005) 1.49
SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem (2002) 1.48
MAPKAP kinase 3pK phosphorylates and regulates chromatin association of the polycomb group protein Bmi1. J Biol Chem (2004) 1.48
Rac1 and PAK1 are upstream of IKK-epsilon and TBK-1 in the viral activation of interferon regulatory factor-3. FEBS Lett (2004) 1.47
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol (2002) 1.43
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res (2010) 1.43
Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol (2006) 1.43
Interplay between influenza A virus and the innate immune signaling. Microbes Infect (2009) 1.43
Effective T-cell recall responses require the taurine transporter Taut. Eur J Immunol (2012) 1.42
The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis. Cell Signal (2012) 1.40
The niche of stellate cells within rat liver. Hepatology (2009) 1.40
BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol (2009) 1.38
Real time analysis of STAT3 nucleocytoplasmic shuttling. J Biol Chem (2003) 1.38
Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev (2012) 1.38
Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol (2003) 1.36
Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon-I-dependent manner in mice. Hepatology (2010) 1.33
Real-time imaging with the sonographic contrast agent SonoVue: differentiation between benign and malignant hepatic lesions. J Ultrasound Med (2004) 1.31
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther (2010) 1.31
Nucleocytoplasmic shuttling of persistently activated STAT3. J Cell Sci (2007) 1.31
Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction. J Immunol (2002) 1.29
Hepatic stem cell niches. J Clin Invest (2013) 1.29
Pathogenicity of different PR8 influenza A virus variants in mice is determined by both viral and host factors. Virology (2011) 1.28
Regulation of suppressor of cytokine signaling 3 (SOCS3) mRNA stability by TNF-alpha involves activation of the MKK6/p38MAPK/MK2 cascade. J Immunol (2007) 1.27
Hepatic encephalopathy and fitness to drive. Gastroenterology (2009) 1.26
Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J Biol Chem (2003) 1.25
Erk5 activation elicits a vasoprotective endothelial phenotype via induction of Kruppel-like factor 4 (KLF4). J Biol Chem (2010) 1.25
Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology (2005) 1.24
A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. Antiviral Res (2007) 1.24
Co-reactivity of plasmodial histidine-rich protein 2 and aldolase on a combined immuno-chromographic-malaria dipstick (ICT) as a potential semi-quantitative marker of high Plasmodium falciparum parasitaemia. Parasitol Res (2004) 1.24